CureVac N.V. EBIT

The latest EBIT for CVAC is $-150M as of November 2025. That compares with $140M in the prior-year period — down 210.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside CureVac N.V.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, CVAC's EBIT moved from $140M to $-150M — a 210.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CureVac N.V.'s operating scale or balance-sheet position.

Against Healthcare companies, CVAC currently prints $-150M for EBIT, while the sector average sits near $110B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at CureVac N.V.'s growth, margins, and balance sheet.

A EBIT figure of $-150M for CVAC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting CVAC's EBIT ($-150M), review year-over-year change from $140M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.